Modality
mRNA
MOA
MALT1i
Target
KRASG12C
Pathway
STING
RBMigraine
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Jul 2029
Phase 1Current
NCT06503168
1,700 pts·Migraine
2023-04→2029-07·Recruiting
NCT04613660
22 pts·RB
2017-02→TBD·Not yet recruiting
1,722 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-033mo agoEnrollment Complete· Migraine
2029-07-173.3y awayInterim· Migraine
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Not yet…
P1
Recruit…
Catalysts
Enrollment Complete
2026-01-03 · 3mo ago
Migraine
Interim
2029-07-17 · 3.3y away
Migraine
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06503168 | Phase 1 | Migraine | Recruiting | 1700 | SRI-4 |
| NCT04613660 | Phase 1 | RB | Not yet recr... | 22 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |